A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 27 Apr 2019
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Encorafenib (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Array BioPharma
- 16 Apr 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2019 This trial has been completed in Germany, according to Eudra record.
- 20 Mar 2019 This trial has been completed in Belgium(End-date-2019-02-12), according to Eudra record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History